Ironwood Pharmaceuticals Inc

Most Recent

  • uploads///Graph Part  Oct
    Company & Industry Overviews

    Radius Continued to Fall despite Positive Data on Osteoporosis

    Radius closed at $49.80 on October 13, 2015. During this period, it fell ~34%. Radius is trading below the 20-day, 50-day, and 100-day moving averages.

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Chimerix Falls 80% following Phase 3 Trial of Brincidofovir

    Chimerix closed at $6.62, and its market-cap fell from $1.6 billion to $305 million on December 28, 2015.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Arena Rose 14% in XBI’s Small-Cap Space

    Arena Pharmaceuticals (ARNA) rose 14% on November 2, 2015. The stock went up on high trading volumes with ~4.7 million shares being traded.

    By Peter Neil
  • uploads///TSRO
    Company & Industry Overviews

    Here’s What Tesaro’s Valuation Trend Indicates

    Tesaro stock has been on a downward trajectory for the past 52 weeks. From a high of $135 on September 5, 2017, it has corrected to $27 in August.

    By Kenneth Smith
  • uploads///Salix
    Company & Industry Overviews

    How Is Bausch Health’s Salix Pharmaceuticals Positioned?

    Bausch Health Companies’ (BHC) wholly-owned subsidiary Salix Pharmaceuticals reported revenue of $441 million in the second quarter.

    By Daniel Collins
  • uploads///NKTR
    Company & Industry Overviews

    What Does Nektar Therapeutics’ Valuation Trend Indicate?

    Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY).

    By Kenneth Smith
  • uploads///capsule _
    Company & Industry Overviews

    What’s the Upside Potential of Nektar Therapeutics?

    Of the 12 analysts covering Nektar Therapeutics in June 2018, 11 analysts have given the stock a “buy” or higher rating.

    By Kenneth Smith
  • uploads///Sucampo Revenue Growth
    Company & Industry Overviews

    The Financial Performance of Sucampo Pharmaceuticals

    Sucampo Pharmaceuticals (SCMP) generated revenues of $61.2 million in 3Q17 compared with $57 million in 3Q16.

    By Kenneth Smith
  • uploads///VTS
    Company & Industry Overviews

    Sucampo Pharmaceuticals’ Amitiza: Its Competitive Landscape

    In the branded prescription category, Amitiza competes with Ironwood Pharmaceuticals (IRWD) and Allergan’s (AGN) Linzess.

    By Kenneth Smith
  • uploads///Key risks facing Synergy Pharmaceuticals
    Company & Industry Overviews

    Synergy Pharmaceuticals Is Facing These Risks This November

    Synergy only started earning revenues after the launch of Trulance in March 2017. Prior to that, Synergy hadn’t earned any revenues.

    By Kenneth Smith
  • uploads///Synergy Pharma RD Expenses Trend
    Company & Industry Overviews

    Behind Synergy Pharmaceuticals’ Financials Today

    Synergy (SGYP) incurred R&D (research and development) expenses of ~$90 million, $78 million, and $ 83 million in fiscal 2016, 2015, and 2014, respectively.

    By Kenneth Smith
  • uploads///Synergy Pharmas Trulance performance
    Company & Industry Overviews

    An Overview of Trulance: Synergy Pharmaceuticals’ First Commercialized Drug

    Since its launch, Synergy’s (SGYP) Trulance sales have been steadily rising. In 3Q17, more than 25,000 prescriptions were filled for the drug.

    By Kenneth Smith
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI’s Holdings: What’s the Trend in Its Moving Averages?

    On June 15, 2016, XBI closed at $54.74. It was trading above its 20-day and 50-day moving averages. XBI’s 20-day moving average is $56.30.

    By Peter Neil
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca’s Recent Products: Approvals and Designations

    AstraZeneca’s (AZN) recent product developments include four drugs that have recently received approvals from regulatory authorities. Four other drugs have received regulatory designations.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Will AstraZeneca’s Corporate Developments Help?

    In this part, we’ll look at some of AstraZeneca’s corporate developments. It entered into some collaborative agreements in 1Q16, including drug development and commercialization rights.

    By Mike Benson
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    IBB Small-Caps Reduce Negative Returns in December

    The small-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) rose 1.4% on December 21, 2015, and reduced the negative returns.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Immunogen Topped the Small-Cap Stocks with High Volumes

    Immunogen rose by 7.2% as of November 25, 2015. The stock rose on the high trading volume. It closed at $13.76. It passed the 100-day moving average price.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Celldex Leads the Small-Cap Stocks in IBB

    Celldex rose by 12.3%. This is the second consecutive trading session the stock gained after it presented varlilumab data at the SITC Annual Meeting 2015.

    By Peter Neil
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    IBB’s Top Ten Small-Cap Stocks Rose Handsomely

    The top ten small-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) outperformed the IBB and the SPDR S&P 500 ETF (SPY) with an average return of 6.25%.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.